ACE inhibitors as a class reduced average trough blood pressure by -8/-5 mm Hg at one-half the maximum recommended dose and above, with no clinically meaningful differences between different agents.
Systematic Review (n=12,954)
Double-blind
Does fixed-dose monotherapy with an ACE inhibitor reduce blood pressure in patients with primary hypertension compared to placebo?
ACE inhibitors provide a modest blood pressure lowering effect of approximately -8/-5 mm Hg, with 60-70% of this effect achieved at recommended starting doses, and no clinically meaningful differences between different ACE inhibitors.
BACKGROUND: ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE). OBJECTIVES: To quantify the dose-related systolic and/or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension. SEARCH STRATEGY: We searched CENTRAL (The Cochrane Library 2007, Issue 1), MEDLINE (1966 to February 2007), EMBASE (1988 to February 2007) and reference lists of articles. SELECTION CRITERIA: Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of fixed-dose monotherapy with an ACE inhibitor compared with placebo for a duration of 3 to 12 weeks in patients with primary hypertension. DATA COLLECTION AND ANALYSIS: Two authors independently assessed the risk of bias and extracted data. Study authors were contacted for additional information. WDAE information was collected from the trials. MAIN RESULTS: Ninety two trials evaluated the dose-related trough BP lowering efficacy of 14 different ACE inhibitors in 12 954 participants with a baseline BP of 157/101 mm Hg. The data do not suggest that any one ACE inhibitor is better or worse at lowering BP. A dose of 1/8 or 1/4 of the manufacturer's maximum recommended daily dose (Max) achieved a BP lowering effect that was 60 to 70% of the BP lowering effect of Max. A dose of 1/2 Max achieved a BP lowering effect that was 90% of Max. ACE inhibitor doses above Max did not significantly lower BP more than Max. Combining the effects of 1/2 Max and higher doses gives an estimate of the average trough BP lowering efficacy for ACE inhibitors as a class of drugs of -8 mm Hg for SBP and -5 mm Hg for DBP. ACE inhibitors reduced BP measured 1 to 12 hours after the dose by about 11/6 mm Hg. AUTHORS' CONCLUSIONS: There are no clinically meaningful BP lowering differences between different ACE inhibitors. The BP lowering effect of ACE inhibitors is modest; the magnitude of trough BP lowering at one-half the manufacturers' maximum recommended dose and above is -8/-5 mm Hg. Furthermore, 60 to 70% of this trough BP lowering effect occurs with recommended starting doses. The review did not provide a good estimate of the incidence of harms associated with ACE inhibitors because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.
Heran et al. (Wed,) conducted a systematic review in primary hypertension (n=12,954). ACE inhibitors vs. placebo was evaluated on dose-related systolic and/or diastolic BP lowering efficacy. ACE inhibitors as a class reduced average trough blood pressure by -8/-5 mm Hg at one-half the maximum recommended dose and above, with no clinically meaningful differences between different agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: